Monday, 17 December 2018 03:07

PHARMAC announces funded Maviret from Feb 1st 2019

Written by
Rate this item
(0 votes)

In an announcement worthy of 3 dancing bananas Woohoo!, PHARMAC in New Zealand have just announced:

We are pleased to announce a decision to fund a new treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret) from 1 February 2019, and to widen access to adalimumab (Humira) for patients with psoriasis from 1 July 2019, through an agreement with AbbVie Ltd.

In summary, this decision will result in the following:

On 1 February 2019:

  • Glecaprevir with pibrentasvir (Maviret) tablets will be funded in the community and DHB hospitals without restrictions for patients with chronic hepatitis C. Maviret treats all genotypes of hepatitis C.
  • Maviret will replace the currently funded open-listed hepatitis C treatment, Viekira Pak (+/- RBV), which will be delisted on the same day. Viekira Pak can only be used to treat patients with genotype 1 hepatitis C.

For more details see the attached press release.

Read 283 times Last modified on Monday, 17 December 2018 03:24

Copyright © 2015-2019 FixHepC

Back to Top